Crohn's Disease Ulcerative Colitis (drugs S-Z)



Thrifty R.) White **PHARMACY** toll-free phone 855.611.3399 Specialty Services toll-free fax 855.423.8300

(Simponi [®] , Stelara [®])			Specialty	Services	toll-free fax 855.423	.8300			
Patient Information				Prescriber + Shipping Information					
Patient name: DOB:				per name:	:				
Sex: 🗆 Female 🗆 N	lale SSN:								
Language:	Wt:	_ □kg □lbs Ht:□cm □in	Address	s:					
Address:			Apt/Suit	e:	_ City:	Sta	ate: Zip: _		
Apt/Suite: City: State: Zip:				:					
Phone: Alternate:				Phone: Alternate:					
Caregiver name: Relation:			Fax:						
Local pharmacy:	acy: Phone:			Email:					
Insurance plan: Plan ID:				If shipping to prescriber: D First Fill D Always Never					
Please fax a copy of front and back of the insurance card(s).									
		pertinent clinical and lab inform							
Crohn's Disease:	□ K50.0 (Crohn's	s Disease of the Small Intenstine)		K50.1 (0	Crohn's Diseas	e of the La	rge Intenstine)		
Crohn's Disease: □ K50.0 (Crohn's Disease of the Small Intenstine) □ K50.1 (Crohn's Disease of the Large Intenstine) □ K50.8 (Crohn's Disease of Both Intenstines) □ K50.9 (Crohn's Disease, unspecified) □ Userative Colities □ K51.0 (Ulgerative Restoration)								•)	
Ulcerative Colitis: K51.0 (Ulcerative Pancolitis) K51.5 (Left Sided Colitis) K51.8 (Other Ulcerative Colitis) K51.9 (Ulcerative Colitis)									
					,	(,	
Diagnosis Date:		TB Test: 🛛 Yes 🗅 No Neg	g. Test Da	te:					
Prior Therapy	Yes 🛛 No	Reason for Discontinuation of T	herapy	Approximate S		Start Date	Approximate End	d Date	
Comorbidition									
Comorbidities: Concomitant Medications:									
Allergies: Allergies:									
Prescription									
Frescription									
-	imzia [®] and Hum	ira [®] are available on the Crohn'	s Disease	e/Ulcerati	ive Colitis Enı	ollment Fo	orm A-R §		
-					ive Colitis Eni		orm A-R §		
§ C		<i>ira[®] are available on the Crohn's</i> g subcut at week 0, then 100 mg a			ive Colitis Enr 00 mg/mL		-	0	
§ C □ Simponi [®]						□ SmartJ □ PFS	lect [®] Autoinjector	0	
§ C	□ Inject 200 m			□ 3 x 1		SmartJPFSSmartJ	-	0	
§ C □ Simponi [®]	 Inject 200 mg Inject 100 mg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks	at week 2	□ 3 x 1	00 mg/mL	□ SmartJ □ PFS	lect [®] Autoinjector	0	
§ C □ Simponi [®]	 Inject 200 mg Inject 100 mg Infuse 260 mg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than	at week 2	□ 3 x 1 □ 1 x 1	00 mg/mL	SmartJPFSSmartJ	lect [®] Autoinjector	0	
§ C □ Simponi [®] (golimumab)	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 mg hour (≤55kg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than)	at week 2	□ 3 x 1 □ 1 x 1 □ 2 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL	SmartJPFSSmartJ	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than	at week 2	□ 3 x 1 □ 1 x 1 □ 2 x 1	00 mg/mL 00 mg/mL	SmartJPFSSmartJ	lect [®] Autoinjector	0	
§ C □ Simponi [®] (golimumab)	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg)	one	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL	 SmartJ PFS SmartJ PFS 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than	one	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL	 SmartJ PFS SmartJ PFS 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than)	one	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL	 ❑ SmartJ ❑ PFS ❑ SmartJ ❑ PFS ❑ Vials 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than	one one one	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL	 SmartJ PFS SmartJ PFS 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft	one one one one er	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL	 ❑ SmartJ ❑ PFS ❑ SmartJ ❑ PFS ❑ Vials 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of Patient eligible 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than i) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: □ Yes □	one one one one er	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL	 ❑ SmartJ ❑ PFS ❑ SmartJ ❑ PFS ❑ Vials 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®] (ustekinumab)	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of Patient eligible □ Date of last infu 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: □ Yes □ usion:	one one one er No	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1 □ 1 x 9	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 10 mg/mL	 Smart. PFS Smart. PFS Vials PFS 	lect [®] Autoinjector		
§ C □ Simponi [®] (golimumab) □ Stelara [®]	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of Patient eligible □ Date of last infu 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: □ Yes □ usion:	one one one er No	□ 3 x 1 □ 1 x 1 □ 2 x 1 □ 3 x 1 □ 4 x 1 □ 1 x 9	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL	 Smart. PFS Smart. PFS Vials PFS 	lect [®] Autoinjector		
§ C Simponi [®] (golimumab) Stelara [®] (ustekinumab) Injection Training P	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous o □ Patient eligible □ Date of last infu rovided by: □ F 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: Yes usion:	one one one er No 	 3 x 1 1 x 1 2 x 1 3 x 1 4 x 1 1 x 9 er: 	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 10 mg/mL	 Smart. PFS Smart. PFS Vials PFS 	lect [®] Autoinjector	0	
§ C Simponi [®] (golimumab) Stelara [®] (ustekinumab) Injection Training P	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous o □ Patient eligible □ Date of last infu rovided by: □ F 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: Yes usion: Physician's Office Pharmacy will be dispensed as generic, if ap	at week 2 one one er No 	3 x 1 1 x 1 2 x 1 3 x 1 3 x 1 4 x 1 1 x 9 er:	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 10 mg/mL	 Smart. PFS Smart. PFS Vials PFS 	lect [®] Autoinjector	0	
§ C Simponi [®] (golimumab) Stelara [®] (ustekinumab) Injection Training P Per state-specific la	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of Patient eligible □ Date of last infut rovided by: □ F w, prescriptions w 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: Yes usion:	at week 2 one one er No 	3 x 1 1 x 1 2 x 1 3 x 1 3 x 1 4 x 1 1 x 9 er:	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 10 mg/mL	 Smart. PFS Smart. PFS Vials PFS 	lect [®] Autoinjector	0	
§ C Simponi [®] (golimumab) Stelara [®] (ustekinumab) Injection Training P	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of □ Patient eligible □ Date of last infut rovided by: □ F w, prescriptions of 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: Yes usion: Physician's Office Pharmacy will be dispensed as generic, if ap <i>Stamp signature not allowe</i>	at week 2 one one one er one identification one one d, physician s	3 x 1 1 x 1 2 x 1 3 x 1 3 x 1 3 x 1 4 x 1 4 x 1 1 x 9 er:	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 00 mg/mL tated otherwise	SmartJ FS SmartJ FS Vials PFS	lect [®] Autoinjector	0	
§ C Simponi [®] (golimumab) Stelara [®] (ustekinumab) Injection Training P Per state-specific la	 □ Inject 200 mg □ Inject 100 mg □ Infuse 260 m hour (≤55kg □ Infuse 390 m hour (>55 kg □ Infuse 520 m hour (>85 kg □ Inject 90 mg intravenous of Patient eligible □ Date of last infut rovided by: □ F w, prescriptions w 	g subcut at week 0, then 100 mg a g subcut every 4 weeks ng intravenously over no less than) ng intravenously over no less than g to <85 kg) ng intravenously over no less than) subcut 8 weeks following initial dose, then every 8 weeks thereaft for self-administration: Yes usion: Physician's Office Pharmacy will be dispensed as generic, if ap	at week 2 one one one er No Oth plicable, u gent to initiate and	3 x 1 1 x 1 2 x 1 3 x 1 3 x 1 3 x 1 4 x 1 4 x 1 1 x 9 er: inless not ignature req	00 mg/mL 00 mg/mL 30 mg/26 mL 30 mg/26 mL 30 mg/26 mL 30 mg/26mL 00 mg/mL tated otherwise uired.	SmartJ FS SmartJ FS Vials PFS PFS	lect [®] Autoinjector	0	

internation which is exempt norm inscrepting the internation advect applicable laws, including the relation instruction and accountability Act (IntPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 855-611-3399 or by emailing specialty@thriftywhite.com to obtain instructions as to the proper destruction of the transmitted material. Thank you.

Updated on 08/17